MAIA Biotechnology (MAIA) News Today $1.46 -0.04 (-2.67%) Closing price 04/7/2025 04:10 PM EasternExtended Trading$1.50 +0.04 (+2.40%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to ShareholdersApril 1, 2025 | businesswire.comIs MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comMAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025March 25, 2025 | businesswire.comMAIA Biotechnology Gets USAN Approval For "Ateganosine" As Name For Telomere-Targeting DrugMarch 21, 2025 | nasdaq.comMAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimerMarch 21, 2025 | msn.comMAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO ProdrugMarch 20, 2025 | businesswire.comMAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIOMarch 19, 2025 | uk.finance.yahoo.comMAIA Biotechnology, Inc. (MAIA) Receives a Buy from Noble FinancialFebruary 28, 2025 | markets.businessinsider.comMAIA Biotechnology to initiate THIO-104 trialFebruary 28, 2025 | markets.businessinsider.comMAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer PatientsFebruary 27, 2025 | businesswire.comMAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung CancerFebruary 26, 2025 | uk.finance.yahoo.comMAIA Biotech announces trial design to expand THIO-101 Phase 2 NSCLC studyFebruary 26, 2025 | markets.businessinsider.comMAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung CancerFebruary 26, 2025 | businesswire.comMAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 MillionFebruary 24, 2025 | finance.yahoo.comMaia Biotechnology Inc trading resumesFebruary 19, 2025 | markets.businessinsider.comMAIA Biotechnology to sell 1.81M shares at $1.50 in private placementFebruary 19, 2025 | markets.businessinsider.comMaia Biotechnology Inc trading halted, news pendingFebruary 18, 2025 | markets.businessinsider.comMAIA Biotechnology Announces Private Placement of $2,715,000February 18, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)February 13, 2025 | markets.businessinsider.comMAIA Biotech executives receive salary hikes and new termsFebruary 7, 2025 | msn.comMAIA Biotechnology Updates Executive Compensation PackagesFebruary 6, 2025 | tipranks.comMAIA Biotechnology reports promising THIO trial results for NSCLCFebruary 5, 2025 | msn.comMAIA Biotechnology Reports Promising Phase 2 Trial ResultsFebruary 5, 2025 | tipranks.comMAIA Biotechnology announces updated data from THIO-101 trialFebruary 5, 2025 | msn.comMAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneFebruary 5, 2025 | msn.comMAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung CancerFebruary 4, 2025 | businesswire.comMAIA Biotechnology to Present at Biotech Showcase 2025January 10, 2025 | businesswire.comMAIA Biotechnology enters clinical supply agreement with BeiGene for THIOJanuary 8, 2025 | markets.businessinsider.comHealth Care Up as Vaccine Makers Surge -- Health Care RoundupJanuary 7, 2025 | marketwatch.comMAIA Biotechnology Shares Rise After Supply Agreement With BeiGeneJanuary 7, 2025 | marketwatch.comMAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer IndicationsJanuary 7, 2025 | finance.yahoo.comMAIA Biotechnology Announces Director Participation in Recent Private Placement ClosingsDecember 19, 2024 | finance.yahoo.comNoble Financial Remains a Buy on MAIA Biotechnology, Inc. (MAIA)December 18, 2024 | markets.businessinsider.comMAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade GliomasDecember 16, 2024 | businesswire.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Purchases $46,750.00 in StockDecember 14, 2024 | insidertrades.comStan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) StockMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith purchased 25,000 shares of the company's stock in a transaction dated Friday, December 13th. The shares were purchased at an average cost of $1.87 per share, for a total transaction of $46,750.00. Following the transaction, the director now directly owns 1,130,060 shares in the company, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.December 13, 2024 | marketbeat.comMAIA Biotechnology announces $950,000 private placementDecember 10, 2024 | msn.comMAIA Biotechnology Announces Private Placement of Approximately $950,000December 9, 2024 | finance.yahoo.comMAIA Biotechnology, Regeneron expand clinical supply agreementDecember 4, 2024 | markets.businessinsider.comMAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung CancerDecember 3, 2024 | businesswire.comDiamond Equity Estimates MAIA Biotechnology Q1 EarningsMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) - Research analysts at Diamond Equity issued their Q1 2025 earnings estimates for shares of MAIA Biotechnology in a research note issued to investors on Thursday, November 14th. Diamond Equity analyst H. Diamond expects that the company wNovember 18, 2024 | marketbeat.comMAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private PlacementNovember 8, 2024 | finance.yahoo.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Cristian Luput Buys 22,133 SharesNovember 5, 2024 | insidertrades.comInsider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of StockMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Cristian Luput bought 22,133 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the transaction, the director now directly owns 389,483 shares of the company's stock, valued at $977,602.33. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.November 4, 2024 | marketbeat.comMAIA Biotechnology prices $2.44M private placementOctober 29, 2024 | msn.comMAIA Biotechnology Announces $2.44 Million Private PlacementOctober 28, 2024 | finance.yahoo.comMAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% - Time to Sell?MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% - Here's WhyOctober 25, 2024 | marketbeat.comMAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer TherapeuticsOctober 15, 2024 | finance.yahoo.comBurberry's Scarf With Spiber, Corium Biotech Raises Seed Funding, Retail Vets Launch Social Studies ShopOctober 8, 2024 | msn.comMAIA Biotechnology (AMEX:MAIA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.com Remove Ads Get MAIA Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for MAIA and its competitors with MarketBeat's FREE daily newsletter. Email Address MAIA Media Mentions By Week MAIA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MAIA News Sentiment▼0.000.63▲Average Medical News Sentiment MAIA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MAIA Articles This Week▼01▲MAIA Articles Average Week Remove Ads Get MAIA Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for MAIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LYEL News TARA News FULC News IVA News IKT News FDMT News IPHA News TNGX News KOD News PBYI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MAIA) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredDividend cuts are destroying retirements… is yours next?The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThese obscure companies are Trump’s favorites?Ten investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MAIA Stock Free MAIA Stock Alerts